[www.journalpulmonology.org](http://www.journalpulmonology.org)


### ORIGINAL ARTICLE

## Benefits and costs of home pedometer assisted physical activity in patients with COPD. A preliminary randomized controlled trial

### K. Widyastuti [a][,][∗], D.N. Makhabah [a], A.Rima Setijadi [a], Y.S. Sutanto [a], Suradi [a], N. Ambrosino [b]

a Pulmonology _Department,_ _Medical_ _Faculty,_ _Sebelas_ _Maret_ _University/Dr._ _Moewardi_ _Hospital,_ _Surakarta,_ _Central_ _Jawa,_ _Indonesia_
b Istituti _Clinici_ _Scientifici_ _Maugeri:_ _Scientific_ _Institute,_ _IRCCS,_ _Montescano,_ _Italy_


Received


28 October 2017; accepted 26 January 2018


##### KEYWORDS
Exercise training;
Dyspnea;
Quality of life;

Exercise tolerance;

Physical activity


**Abstract**
_Background_ _and_ _objective:_ There are barriers to providing pulmonary rehabilitation for chronic

obstructive pulmonary disease (COPD) such as the high number of patients, difficult access to

health facilities and high costs of programs. Pedometers can monitor and improve physical

activity (PA). The aim of this study was to evaluate benefits and costs of home pedometer

assisted PA, as compared to a standard outpatient supervised exercise training program in

patients with COPD.

_Methods:_ Patients were randomly assigned either to home pedometer assisted PA (Group 1),

or to a six-week outpatient standard supervised exercise training program (Group 2). Patients

of Group 1 had to walk at home for 6 weeks, at least 30 min daily at the fastest step pace as

possible, to achieve a weekly 10% increase in their average daily steps up to more than 6500.

Pre and post programs we assessed: the six minute walking distance (6MWT: primary outcome),

daily steps count, the Medical Research Council scale (MRC), the COPD assessment test score,

and the BODE index (body-mass index, airflow obstruction, dyspnea, exercise capacity). Costs

of programs were also evaluated.


_Abbreviations:_ 6MWT, six-minute walking test; ATS, American Thoracic Society; BMI, Body-mass Index; BODE, Body-mass index, airflow
obstruction, dyspnea, and exercise capacity index; CAT, COPD Assessment Test; CONSORT, Consolidated Standards of Reporting Tables; COPD,
chronic obstructive pulmonary disease; ERS, European Respiratory Society; FEV1, Forced Expiratory Volume at one second; GOLD, Global

Initiative for Chronic Obstructive Pulmonary Disease; HRQL, health-related quality of life; IDR, Indonesian rupiah; MCID, Minimum Clinically
Important Difference; MRC, Medical Research Council score; PA, physical activity; QALY, quality adjusted life years; RCT, Randomised
Controlled Trial; SD, Standard Deviation.
∗ Corresponding author.
_E-mail_ _address:_ [dr.kikiwidy@gmail.com](mailto:dr.kikiwidy@gmail.com) (K. Widyastuti).

[https://doi.org/10.1016/j.pulmoe.2018.01.006](https://doi.org/10.1016/j.pulmoe.2018.01.006)
2531-0437/© 2018 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espa˜na, S.L.U. This is an open access article under the CC
BY-NC-ND license [(http://creativecommons.org/licenses/by-nc-nd/4.0/).](http://creativecommons.org/licenses/by-nc-nd/4.0/)


-----

_Results:_ Out of 40 patients, 18 in both groups (mean (standard deviation)) age: 68.3 (6.7) and
61.2 (6.7) years; FEV1: 1.1 (0.5) and 0.9 (0.4) liters in Group 1 and 2 respectively completed the

study. At the end of the program 44.5% patients of Group 1 had reached the target daily steps,

in 26.6 (9.5) days. Following the programs, both groups showed significant improvements in all

outcome measures, except BODE. The home program was cheaper (p = 0.0001), with a mean
76.3 euros saving per patient.

_Conclusion:_ Home pedometer assisted PA may be a useful and cheaper alternative to outpatient

supervised exercise training programs in patients with COPD.

© 2018 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espa˜na, S.L.U. This is an

open access article under the CC BY-NC-ND license [(http://creativecommons.org/licenses/by-](http://creativecommons.org/licenses/by-nc-nd/4.0/)

[nc-nd/4.0/).](http://creativecommons.org/licenses/by-nc-nd/4.0/)


#### Introduction

Total tobacco-attributable deaths including those due to
chronic obstructive pulmonary disease (COPD), a leading
cause of mortality and morbidity worldwide are projected to

rise from 5.4 million in 2005 to 8.3 million in 2030.[1---4] Prevalence and mortality rate are forecasted to increase due to

the increasing number of smokers.[2---6]

Higher physical activity (PA) is associated with lower
risk of mortality and cardiovascular events in individuals
from low-, middle-, and high-income countries.[7] Daily PA of

patients with COPD is reduced in the early phases of disease
as compared to healthy age-matched controls[8] and worsen
over time, with important clinical consequences.[9] In these

patients pulmonary rehabilitation improves symptoms, exercise capacity and health-related quality of life (HRQL),[10,11]

although the observed benefits do not consistently translate
into enhanced PA levels.[12] As a consequence guidelines for
management of COPD suggest that pulmonary rehabilitation

including exercise training should be provided to the vast
majority of patients.[1]

In many countries, there are barriers to hospital based
inpatient and outpatient supervised exercise training programs, such as a high number of patients, transportation,
program costs, and geographical obstacles.[13] A home pro
gram consisting of 3 weekly sessions for 8 weeks of aerobic
leg cycling and strength exercises was a useful, equivalent

alternative to outpatient rehabilitation for patients with

COPD.[14] Also tele-rehabilitation programs may be potentially useful to deliver and to maintain the benefits in
difficult-to-reach areas.[15,16]

The daily steps and activity time were proven to be the
most valid measurement of PA[17,18] and their regular monitoring may benefit patients with COPD in achieving the
effective daily PA.[18] Pedometers have greatly advanced in

recent years, providing daily step estimates,[18] and smart
phones with miniaturized accelerometre apps measuring PA

are universal, widespread technologies which many patients

with COPD may not use as they probably should.
We hypothesized that a home pedometer assisted pro
gram to incentivize PA might be an alternative to hospital
based outpatient exercise training programs, especially in

the context of regional asymmetries and difficult access to

health facilities (as is the case of Indonesia with a 4.5% COPD
prevalence,[5] and a population of about 260 million --- about


35 million living in Central Jawa, the others living on more

than 17 000 islands with limited access to health services[19]).

The aim of this study was to evaluate the effect on exercise

capacity, PA, dyspnea, and health status as well as costs of

home pedometer assisted PA, as compared to a standard

outpatient supervised exercise training program in patients

with COPD.

#### Methods

##### Study design


This was a randomized clinical trial (RCT). During the first
week, all patients were taught how to use pedometers

in three face to face sessions with a researcher checking
patients’ ability to use the device properly. After the train
ing week, subjects were randomly assigned to two groups:

the Study Group (Group 1) received an unsupervised home
pedometer assisted PA program, the Control Group (Group

2) received a hospital based outpatient supervised exercise training program. Researchers evaluating results and

patients were not blind to treatment. Patients maintained

their usual drug medication during the entire study.
The study was performed according to the Helsinki

Declaration and approved by the Ethics Committee of
Dr. Moewardi Hospital, Surakarta, Central Jawa, Indonesia

(Reference: 799/IX/HREC/2016). Written informed consent

to participate was obtained from all participants.

##### Study participants


Stable patients suffering from COPD as defined by the
Global Initiative for Chronic Obstructive Pulmonary Disease

(GOLD) guidelines,[1] 40---75 years old, were consecutively
recruited from the outpatient clinic of Dr. Moewardi Hos
pital, Surakarta, Central Jawa, Indonesia, between October

2016 and January 2017. Patients were enrolled if in a stable
clinical condition (no exacerbation in the 4 weeks prior to
study). The exclusion criteria were refusal to participate,

participation in a pulmonary rehabilitation program during

the previous 6 months, and severe concomitant comorbidi
ties such as ischemic cardiac disease, chronic heart failure,

orthopedic and/or neuromuscular diseases interfering with
their ability to walk.


-----

##### Study procedures

Patients of Group 1 received a pedometer (Omron HJ 321,
Omron Healthcare Co Ltd, Kyoto, Japan) with the task of

walking at home for 6 weeks. They were instructed to record

the number of daily steps in their activity log books, along
with information on any change in their clinical conditions.
They were also asked to walk at home at the fastest step

pace as possible, for at least 30 min every day, for up to 6

weeks, with the task of achieving a weekly 10% increase in
their average daily steps eventually reaching more than 6500

daily steps. Doctors checked both the patients’ pedometers

and activity logbooks during weekly meetings at patients’

homes and every two weeks during the meetings at outpatient clinic. On the basis of pedometer daily step count and
activity logbook checks, doctors prescribed the target step

count for the following week.
Group 2 patients received three 30-min weekly sessions

for six weeks of supervised standard exercise training on a
treadmill at outpatient clinics. Doctors and nurses super
vised the sessions. Initial treadmill speed was set at 80%
of their theoretical speed during the six minute walking test
(6MWT) performed at admission and calculated as described

below, at 0 inclination. Depending on patient tolerance, the
treadmill speed could be increased by 0.1 km/h at each

session. Patients were also encouraged to be more active
at home and to walk for at least 30 min daily without any
supervision. They also were instructed to fill in their activity

log books which were checked by doctors every week. Also
these patients were given a pedometer on the day before
the first session and the day after the last session in order

to record the daily steps.


MCID for PA has been reported to be 600---1100 daily
steps.[22]

- The subjective sensation of breathlessness was evaluated
by means of the Medical Research Council (MRC) scale.[23]

One point change in the scale is considered the MCID for
this outcome measure.[24]

- The perceived health status was assessed by the Indonesian Version of the COPD Assessment Test (CAT) score.[25,26]

The MCID for CAT score is reported to be 2 points.[27]

- The composite and multidimensional BODE (body-mass
index, airflow obstruction, dyspnea, and exercise capac
ity) index was calculated for each patient.[28] It has been
shown that for every point increase in the BODE there is

a corresponding increase in mortality.[29]

##### Costs


Costs of programs per patient were assessed according to
a modified calculation proposed by Goldstein et al.[30] and

gathered from the hospital financial department staff. The
following costs were identified: pedometer, doctor consulta
tions and doctor/nurse supervisions during exercise training,

services, and medication. Transportation costs of patients
and professionals to and from the hospital were calculated

as follows: bus ticket cost, multiplied by the number of

patients’ hospital and professionals’ home visits. Costs of
exacerbations, hospital admissions and unscheduled medical
visits were not included.

##### Statistical analysis


##### Measurements

At admission the following data and measurements were
recorded:

- Demographics and anthropometrics, time of first diagnosis, drug therapy.

- Dynamic lung volumes, assessed after bronchodilation and

expressed as absolute and percent of predicted values
according to the Pneumomobile Project Indonesia.[20]


Before and after the programs, the following parameters
were assessed in all patients:

- Exercise tolerance by means of the 6MWT.[21] The best of
two consecutive performances (2-h apart) conducted in
a 30-m long and 3-m wide corridor under quiet condi
tions and without distractive stimuli was recorded for

analysis. The Minimum Clinically Important Difference

(MCID) of 6MWT following exercise training in moderate to severe COPD was recently reported to be at least

a 30 m increase.[21] The distance walked in 6MWT was

also expressed as ‘‘theoretical’’ speed (km/h) multiplying
meters × 10.

- Physical activity was measured as daily steps, based on

an average step count of 7 days obtained using the same

pedometer given to patients at their baseline visit. The


The primary outcome measure was the 6MWT. Results are
shown as mean (Standard Deviation: SD) for continuous and
as numbers (percentage frequency) for discrete variables.

MRC and BODE are shown as median (interquartile range),

whereas the number of steps are presented as mean (SD) as
normally distributed.

To determine the sample size, an earlier study[31] showed
a post-program 70.4 (18.3) meter mean increase in 6MWT.

The study hypothesis was therefore to observe a 30 m postPRP change in both groups. To obtain a 90% study power and

an alpha error less than 5%, a minimum sample size of 12

patients completing the study was required in each Group.
To obtain this result we estimated an allocation sample size

of 40 patients, considering a 20% drop out rate.

Unpaired _t_ test, Kruskall---Wallis _H_ test, and �[2] analyses
for dichotomous variables were used when appropriate for
comparison between groups to test any baseline difference.

The two-way repeated measures ANOVA was carried out to

compare the improvements of both groups. Chi-square test

was used to compare continuous and categorical variables.

A _p_ value less than 0.05 was considered as statistically significant.
Analyses were performed using a specific package (SPSS

for Windows latest version, Chicago, Illinois, USA).

#### Results

Fig. 1 shows the Consolidated Standards of Reporting
Tables (CONSORT) diagram of the study. Out of 40 patients


-----

Analysis (n=18) Analysis (n=18)

**Figure** **1** CONSORT flow diagram.


recruited, 18 patients in each group completed the study.
Two patients were excluded due to an exacerbation, one

patient withdrew his consent, and one patient dropped out
due to a motorcycle crash.
Table 1 shows the demographic, anthropometric, physiological and clinical characteristics of the patients. The two
groups were not different for any characteristic except for

the older age in Group 1 patients.

##### Outcome measures


mainly due to the sessions involving professionals, the costs
of doctors consultations and doctors/nurse supervisions of
outpatient exercise training, and the costs of daily transportations of patients to and from the hospital required by
Group 2 patients.

#### Discussion


Table 2 shows the absolute values of the outcome measures
before and after the programs. At the end of the program
44.5% patients of group 1 had reached the target daily steps,

in 26.6 (9.5) days. Two-way ANOVA showed that following the
programs both groups reported significant improvements in

all measures except BODE.

Table 3 shows the proportion of patients reaching the
MCID in the post PRP evaluation. There was a significant
difference in proportion of patients reaching the MCID only

for the BODE and MRC which were more in Group 2 than in

Group 1. The proportion of patients reaching the MCID in all
outcome measures was greater than 60% only in Group 2.

##### Costs


Table 4 shows the detailed costs of programs per individual patient. Despite the pedometer cost, the home program

was cheaper with a mean 76.3 euros saving per patient.
The median (interquartile range) for grand total cost was

932 000 (36 000) Indonesian Rupias (IDR) or 58.2 (2.2) euros

versus 2 124 000 for (108 000) IDR or 132.7 (6.7) euros for
Group 1 and 2 respectively (p = 0.0001). The difference was


A home pedometer assisted program to incentivize PA was
cheaper than and as effective as a standard outpatient
supervised exercise training program.
The baseline daily step count and 6MWT of our patients
were lower than in other studies. In the study by Vorrink
et al.,[32] the mean daily step count and 6MWT in their inter
vention group were 5824 steps and 465 m as compared to

2513 steps and 193 m respectively, in our study. However
the airway obstruction of our patients was more severe as
shown by a mean FEV1 of 1.1 in our patients as compared to

1.7 l in that study.[32]

Our results showed significant improvements in 6MWT
and daily steps in both groups. However the mean improve
ment in 6MWT of Group 2 was slightly greater, albeit
nonsignificantly, than in Group 1, whereas the change in

daily steps was similar in both groups. This difference indicates the need to specifically assess both exercise capacity

and PA, when evaluating the effects of pulmonary rehabili
tation. Our results are similar to those of Mendoza et al.[33]:
in that randomized study patients with COPD underwent

either a standard program of PA encouragement alone, or a

pedometer-based program. Their pedometer group gained

significant improvements in PA (by 3080 daily steps) and CAT
score (−3.5), similar to our results, and in 6MWT (by 12.4 m),

less than in our patients.[33] An earlier study in Indonesian


-----

**Table** **1** Demographic, antropometric, physiological and clinical characteristics.

Group 1 (n = 18) Group 2 (n = 18) _p_ value

_Age,_ _years_ 68.3 (6.7) 61.2 (6.7) 0.005

_Gender_ 0.630

Male 16 (89%) 15 (83%)

Female 2 (11%) 3 (17%)

_Education_ 0.501

Low 10 (56%) 12(67%)

Middle 6 (33%) 3 (17%)

High 2 (11%) 3 (17%)

_Job_ 0.860

Farmer 4 (22%) 3 (17%)

Service 5 (28%) 4 (22%)

Worker 3 (17%) 5 (28%)

Retired 6 (33%) 6 (33%)

_Smoking_ _status_ _(pack_ _years)_ 21.6 (18.8) 17.4 (13.1) 0.443

Never 2 (11%) 3 (17%)

≤15 pack years 6 (33%) 5 (28%) 0.865

>15 pack years 10 (56%) 10 (56%)

_Comorbidities_ 0.766

0 9 (50%) 10 (56%)

1 2 (11%) 7 (11%)

≥ 2 7 (39%) 1 (6%)

_BMI,_ _kg/m[2]_ 20.3 (4.5) 22.3 (3.4) 0.140

_FEV1,_ _l_ 1.1 (0.5) 0.9 (0.4) 0.495

_FEV1%_ _predicted_ 0.646

<80 3 (17%) 2 (11%)

50---79 8 (44%) 9 (50%)

30---49 6 (33%) 4 (22%)

<30 1 (6%) 3 (17%)

_GOLD_ _stage_

B 9 (50%) 11 (61%) 0.766

C 2 (11%) 2 (11%)

D 7 (39%) 5 (28%)


Data are presented as mean (SD) or _n_ (%), unless otherwise stated.
BMI, Body-mass index; FEV1, Forced Expiratory Volume at one second; GOLD, Global Initiative for Chronic Obstructive Pulmonary Disease.


**Table** **2** Outcome measures before and after programs.

Group 1 Group 2 _p_ value[a]

Before After Before After Group Time Time*Group

Daily steps (n) 2513 (1312) 6021 (2549) 2869 (1154) 6113 (2403) 0.629 0.001 0.775
MRC 1 (1) 1 (0) 2 (1) 1 (1) 0.091 0.006 0.186

6MWT (m) 192.7 (54.7) 242.1 (78.6) 196.4 (62.3) 266.6 (46.7) 0.336 0.001 0.476

CAT 13.8 (4.2) 10.7 (5.1) 13.4 (3.3) 9.1 (3.3) 0.297 0.001 0.523

BODE 4.5 (3) 4 (4) 4 (3) 3 (3) 0.237 0.083 0.397


Daily steps, 6MWT and CAT score are presented as mean (SD), MRC and BODE are shown as median (interquartile range).
MRC, Medical Research Council; 6MWT, six-minute walking test; CAT, COPD Assessment Test; BODE, Body-mass index, airflow obstruction,
dyspnea, and exercise capacity index.
a 2-way repeated measures ANOVA. There was no significant interaction between groups and time.


-----

**Table** **3** Proportion of patients reaching the MCID in the post PRP evaluation.

All subjects (%) Group 1 (%) Group 2 (%) _p_ value

Daily Steps 97.2 100.0 94.4 0.310
MRC 44.4 27.8 61.1 0.044

6MWT 58.3 44.4 72.2 0.091

CAT 77.8 72.2 83.3 0.423

BODE 58.3 38.9 77.8 0.018


_p_ values refer to between group comparison.
MRC, Medical Research Council; 6MWT, six-minute walking test; CAT, COPD Assessment Test; BODE, Body-mass index, airflow obstruction,
dyspnea, and exercise capacity index.


**Table** **4** The costs per program per single patient.

Variables Group 1IDR/Euro Group 2IDR/Euro

_Session_ _cost_
Medical/Nursing/Therapist 70 000/4.4 70 000/4.4

Other service (Maintenance) --- 40 000/2.5

Device 300 000/18.7[a] --

_Total_ _per_ _session_ 70 000/4.4 110 000/6.9

_Total_ _per_ _programs_ 860 000/53.7 1 980 000/123.7

_Transports_ _per_ _sessions_ 55 000/3.4 24 000/1.5[b]

_Transport_ _per_ _programs_ 330 000/20.6 432 000/27.0


Grand total 1 190 000/74.4 2 412 000/150.7[c]

IDR, Indonesian rupiah.
a A pedometer only bought once and can be used for the rest of their life.
b Theoretical formula for transports: (the lowest + the highest costs)/2.
Based on changes for IDR 16 007 = 1 Euro on December 12, 2017.
c p = 0.0001.


COPD patients[31] showed after a 5-week program a mean 44 m
increase in 6MWT, a result similar to that observed in Group

1 of our study. The post-program improvement in exercise

tolerance and in PA observed in our study translated into an
improvement in health status as assessed by the CAT score
and dyspnea as assessed by MRC in both groups. Previous
studies found that MRC, due to its limited number of lev
els, was not sensitive enough to detect small changes after
programs.[34]

In our study the perceived health status was assessed
by the CAT score. A specific HRQL questionnaire such as

the Saint George Respiratory Questionnaire (SGRQ) was not

available at our Institution. Although CAT is correlated to
SGRQ in terms of discriminating health status, there is evi
dence that the SGRQ shows a greater responsiveness in
patients with COPD undergoing pulmonary rehabilitation.[35]

The main findings of our study suggest that independently of the setting, whether home pedometer assisted

or standard outpatient program, our COPD patients gained
similar mean improvements in assessed outcome measures,

except the BODE index. However, from a clinical point of

view, it is important to note that the proportion of patients
reaching the MCID in all outcome measures was greater than
60% only in Group 2. Other studies have reported conflicting

results. A 6-week online-supported pulmonary rehabilitation

program was non-inferior to a conventional program in terms
of effects on 6MWT, and symptom scores; furthermore it was

safe and well tolerated.[36] A home maintenance pulmonary


rehabilitation program was equally as effective as an outpatient hospital, maintenance program in reducing the risk
for acute COPD exacerbations and hospitalizations.[16] Physi
cal activity could be significantly increased in patients with
COPD using a 12-week intervention including a step counter
and a smartphone app.[37] A home pulmonary rehabilitation
program, delivered with minimal resources, produced short
term clinical outcomes similar to a center-based program.[38]

A recent simulation study[39] has reported that pulmonary
rehabilitation was cost-effective in every setting in the

comprehensive management of patients with COPD. In the
programs of our study as a whole the cost per patient of

Group 1 was about half than that of Group 2. In the frame of

Indonesian economy the mean 76.3 euros saving per patient

obtained in Group 1, is not negligible. The cost analysis in

our study involved direct costs and transportation as the only
indirect cost. We were unable to calculate other indirect

costs, such as time spent by relatives to transport patients

to and from the hospital, or costs of exacerbations, hospital

admissions or unscheduled visits. Previous studies reported
a reduction in health service usage in rehabilitated outpa
tients. Griffiths et al.,[40] reported that outpatient pulmonary

rehabilitation produced cost per quality adjusted life years
(QALYs) ratios within bounds considered to be cost effec
tive. In a retrospective case-control study,[41] a short-term,

inpatient pulmonary rehabilitation program induced a shortterm improvement in exercise tolerance, similar to a longer,

outpatient program. The duration of program and the need


-----

for daily transportation significantly influenced the total
costs of the outpatient pulmonary rehabilitation.[41] In a RCT

including an economic evaluation, outpatient pulmonary
rehabilitation appeared highly cost-effective in comparison

with a program incorporating a substantial period of inpatient care.[30,42] Comparisons of cost-effectiveness between

programs performed in different countries, institutions and
health-care systems are difficult because of differences in
case-mix, outcome measures, and the time-points when
outcomes are measured. Therefore, the application of our
results to other health-care systems must be considered with

caution.
Our study has some limitations. We have compared home

pedometer assisted PA with outpatient supervised exercise
training. Stimulated PA and supervised exercise training are

only two of the components of pulmonary rehabilitation

which, according to the ATS/ERS statement,[10] should also
include other multidisciplinary interventions such as educa
tion, and behavior change. Whether a more comprehensive

intervention also including other components as defined

by that statement[10] would have obtained different results,

remain to be evaluated. We have also compared two groups
performing a different number of exercise sessions. On the

other hand our results may indicate also the effectiveness
of our supervised hospital based outpatient program achieving the same benefits as an unsupervised program despite
less exercise sessions. The use of pedometers by the home

program might have introduced some bias to the study, as

standard hospital based programs do not routinely offer this
device. Patients and researchers were not blind to alloca
tion. However, this bias probably would have favored results
of Group 1 which in fact did not show any superiority over

Group 2.
In conclusion with these limitations this preliminary RCT

showed that, at least in our health-care system and for our
patients with COPD, a home pedometer assisted program to
incentivize PA may be a useful and cheaper alternative to
outpatient supervised exercise training programs.

#### Conflicts of interest

The authors have no conflicts of interest to declare.

#### References


1. [Vogelmeier](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [CF,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [Criner](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [GJ,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [Martinez](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [FJ,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [Anzueto](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [A,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [Barnes](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [PJ,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215)
[Bourbeau](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [J,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [et](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [al.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [Global](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [strategy](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [for](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [the](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [diagnosis,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [manage-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215)
[ment](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [prevention](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [Chronic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [Obstructive](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [Lung](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [Disease](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [2017](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215)
[report,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [GOLD](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [Executive](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [Summary.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [Am](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [J](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [Respir](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [Crit](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [Care](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215) [Med.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215)
[2017;195:557---82.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0215)
2. [Lozano](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [R,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [Naghavi](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [M,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [Foreman](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [K,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [Lim](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [S,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [Shibuya](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [K,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [Aboy-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220)
[ans](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [V,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [et](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [al.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [Global](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [regional](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [mortality](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [from](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [235](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [causes](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220)
[of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [death](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [for](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [20](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [age](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [groups](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [1990](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [2010:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [a](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [systematic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220)
[analysis](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [for](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [the](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [Global](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [Burden](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [Disease](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [Study](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [2010.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220) [Lancet.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220)

[2012;380:2095---128.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0220)
3. [Mathers](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225) [CD,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225) [Loncar](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225) [D.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225) [Projections](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225) [global](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225) [mortality](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225) [bur-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225)
[den](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225) [disease](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225) [from](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225) [2002](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225) [to](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225) [2030.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225) [PLoS](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225) [Med.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225) [2006;3:e442.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0225)
4. [GBD](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [2015](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [Chronic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [Respiratory](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [Disease](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [Collaborators.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [Global,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230)
[regional,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [national](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [deaths,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [prevalence,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [disability-adjusted](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230)
[life](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [years,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [years](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [lived](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [with](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [disability](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [for](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [chronic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [obstruc-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230)
[tive](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [pulmonary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [disease](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [asthma,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [1990---2015:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [a](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [systematic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230)


[analysis](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [for](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [the](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [Global](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [Burden](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [Disease](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [Study](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [2015.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [Lancet](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230)
[Respir](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [Med.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230) [2017;5:691---706.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0230)
5. [Lim](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [S,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [Lam](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [DC,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [Muttaliif](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [AR,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [Yunus](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [F,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [Wongtim](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [S,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [Lan](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [LTT,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [et](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [al.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235)
[Impact](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [chronic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [obstructive](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [pulmonary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [disease](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [(COPD)](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [the](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235)
[Asia-Pacific](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [region:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [the](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [EPIC](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [Asia](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [population-based](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [survey.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [Asia](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235)
[Pacific](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [Fam](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [Med.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235) [2015;14:4.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0235)
6. [Regional](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240) [COPD](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240) [Working](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240) [Group.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240) [COPD](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240) [prevalence](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240) [12](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240)
[Asia-Pacific](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240) [countries](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240) [regions:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240) [projection](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240) [based](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240) [on](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240) [the](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240)
[COPD](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240) [prevalence](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240) [estimation](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240) [model.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240) [Respirology.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240) [2003;8:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240)
[192---8.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0240)
7. [Lear](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [SA,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [Hu](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [W,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [Rangarajan](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [S,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [Gasevic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [D,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [Leong](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [D,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [Iqbal](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [R,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245)
[et](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [al.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [The](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [effect](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [physical](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [activity](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [on](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [mortality](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [car-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245)
[diovascular](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [disease](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [130](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [000](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [people](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [from](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [17](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [high-income,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245)
[middle-income,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [low-income](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [countries:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [the](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [PURE](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [study.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245)
[Lancet.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245) [2017;390:2643---54.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0245)
8. [Pitta](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [F,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [Troosters](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [T,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [Spruit](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [MA,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [Probst](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [VS,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [Decramer](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [M,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [Gos-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250)
[selink](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [R.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [Characteristics](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [physical](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [activities](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [daily](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [life](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250)
[chronic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [obstructive](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [pulmonary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [disease.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [Am](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [J](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [Respir](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [Crit](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [Care](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250)
[Med.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250) [2005;171:972---7.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0250)
9. [Waschki](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [B,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [Kirsten](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [AM,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [Holz](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [O,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [Mueller](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [KC,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [Schaper](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [M,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [Sack](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255)
[AL,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [et](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [al.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [Disease](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [progression](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [changes](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [physical](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [activity](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255)
[in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [patients](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [with](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [chronic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [obstructive](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [pulmonary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [disease.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [Am](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [J](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255)
[Respir](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [Crit](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [Care](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [Med.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255) [2015;192:295---306.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0255)

10. [Spruit](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [MA,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [Singh](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [SJ,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [Garvey](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [C,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [ZuWallack](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [R,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [Nici](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [L,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [Rochester](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260)
[C,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [et](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [al.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [An](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [official](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [American](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [Thoracic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [Society/European](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260)
[Respiratory](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [Society](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [statement:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [key](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [concepts](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [advances](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260)
[in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [pulmonary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [rehabilitation.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [Am](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [J](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [Respir](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [Crit](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [Care](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260) [Med.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260)
[2013;188:e13---64.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0260)
11. [Paneroni](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [M,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [Simonelli](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [C,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [Vitacca](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [M,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [Ambrosino](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [N.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [Aerobic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265)
[exercise](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [training](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [very](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [severe](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [chronic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [obstructive](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [pulmonary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265)
[disease:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [a](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [systematic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [review](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [meta-analysis.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [Am](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [J](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [Phys](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [Med](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265)
[Rehabil.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265) [2017;96:541---8.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0265)
12. [Cindy](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [Ng](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [LW,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [Mackney](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [J,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [Jenkins](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [S,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [Hill](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [K.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [Does](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [exercise](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [train-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270)
[ing](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [change](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [physical](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [activity](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [people](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [with](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [COPD?](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [A](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [systematic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270)
[review](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [meta-analysis.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [Chron](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [Respir](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [Dis.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270) [2012;9:17---26.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0270)
13. [Vogiatzis](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [I,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [Rochester](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [CL,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [Spruit](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [MA,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [Troosters](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [T,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [Clini](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [EM.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275)
[Increasing](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [implementation](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [delivery](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [pulmonary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [rehabil-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275)
[itation:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [keymessages](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [from](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [the](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [new](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [ATS/ERS](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [policy](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [statement.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275)
[Eur](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [Respir](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [J.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275) [2016;47:1336---41.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0275)
14. [Maltais](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [F,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [Bourbeau](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [J,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [Shapiro](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [S,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [Lacasse](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [Y,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [Perrault](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [H,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [Baltzan](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280)
[M,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [et](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [al.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [Effects](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [home-based](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [pulmonary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [rehabilitation](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280)
[patients](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [with](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [chronic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [obstructive](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [pulmonary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [disease:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [a](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [random-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280)
[ized](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [trial.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [Ann](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [Intern](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [Med.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280) [2008;149:869---78.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0280)
15. [Ambrosino](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0285) [N,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0285) [Fracchia](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0285) [C.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0285) [The](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0285) [role](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0285) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0285) [tele-medicine](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0285) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0285)

[patients](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0285) [with](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0285) [respiratory](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0285) [diseases.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0285) [Expert](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0285) [Rev](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0285) [Respir](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0285) [Med.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0285)

[2017;11:893---900.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0285)
16. [Vasilopoulou](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [M,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [Papaioannou](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [AI,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [Kaltsakas](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [G,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [Louvaris](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [Z,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290)
[Chynkiamis](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [N,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [Spetsioti](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [S,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [et](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [al.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [Home-based](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [maintenance](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [tele-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290)
[rehabilitation](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [reduces](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [the](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [risk](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [for](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [acute](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [exacerbations](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [COPD,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290)
[hospitalisations](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [emergency](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [department](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [visits.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [Eur](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [Respir](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [J.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290)
[2017:49,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290) [pii:1602129.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0290)
17. [Watz](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [H,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [Pitta](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [F,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [Rochester](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [CL,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [Garcia-Aymerich](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [J,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [ZuWallack](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295)
[R,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [Troosters](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [T,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [et](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [al.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [An](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [official](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [European](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [Respiratory](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [Soci-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295)
[ety](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [statement](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [on](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [physical](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [activity](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [COPD.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [Eur](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [Respir](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295) [J.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295)
[2014;44:1521---37.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0295)
18. [Boeselt](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [T,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [Spielmanns](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [M,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [Nell](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [C,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [Storre](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [JH,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [Windisch](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [W,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300)
[Magerhans](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [L,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [et](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [al.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [Validity](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [usability](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [physical](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [activity](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300)
[monitoring](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [patients](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [with](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [chronic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [obstructive](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [pulmonary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [dis-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300)
[ease](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [(COPD).](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [PLOS](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [ONE.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300) [2016;11:e0157229.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0300)
19. [Statistical](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0305) [yearbook](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0305) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0305) [Indonesia](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0305) [2017.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0305) [BPS-Statistics](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0305) [Indonesia;](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0305)
[2017.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0305) [ISSN:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0305) [0126-2912.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0305) [Publication](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0305) [Number:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0305) [03220.1709.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0305)
20. [Alsagaff](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [H,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [Mangunnegoro](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [H,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [Amin](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [M,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [Yunus](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [F,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [Bernstein](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [RS,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310)
[Johnson](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [L.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [Reference](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [spirometric](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [values](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [healthy](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [indone-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310)
[sian](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [school](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [children](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [working](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [adults,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [using](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [equipment](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310)
[and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [methds](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [that](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [meet](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [ATS](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [1987](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [recommendations.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310) [PARU.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310)
[1992;12:3---18.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0310)
21. [Holland](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [AE,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [Spruit](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [MA,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [Troosters](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [T,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [Puhan](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [MA,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [Pepin](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [V,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [Saey](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [D,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315)
[et](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [al.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [An](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [official](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [European](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [Society/American](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [Thoracic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [Society](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315)


-----

[technical](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [standard:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [field](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [walking](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [tests](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [chronic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [respiratory](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315)
[disease.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [Eur](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [Respir](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [J.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315) [2014;44:1428---46.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0315)
22. [Demeyer](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [H,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [Burtin](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [C,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [Hornixs](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [M,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [Camilli](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [CA,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [Remoorter](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [HV,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320)
[Langer](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [D.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [The](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [minimal](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [important](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [difference](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [physical](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [activity](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320)
[in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [patients](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [with](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [COPD.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [PLOS](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [ONE.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320) [2016;11:e0154587---154598.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0320)
23. [Fletcher](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [CM.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [Standardised](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [questionnaire](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [on](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [respiratory](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [symp-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325)
[toms:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [a](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [statement](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [prepared](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [approved](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [by](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [the](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [MRC](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325)
[Committee](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [on](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [the](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [Aetiology](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [Chronic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [Bronchitis](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [(MRC](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [breath-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325)
[lessness](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [score).](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [Br](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [Med](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [J.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325) [1960;2:1665.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0325)
24. [De](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [Torres](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [JP,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [Pinto-Plata](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [V,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [Ingenito](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [E,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [Bagley](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [P,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [Gray](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [A,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [Berger](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330)
[R,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [et](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [al.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [Power](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [outcome](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [measurements](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [to](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [detect](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [clinically](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330)
[significant](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [changes](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [pulmonary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [rehabilitation](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [patients](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [with](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330)

[COPD.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [Chest.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330) [2002;121:1092---8.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0330)
25. [Perhimpunan](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0335) [Dokter](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0335) [Paru](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0335) [Indonesia.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0335) [PPOK](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0335) [(penyakit](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0335) [paru](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0335)
[obstruktif](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0335) [kronik)](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0335) [diagnosis](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0335) [dan](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0335) [penatalaksanaan.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0335) [Jakarta:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0335)
[PDPI;](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0335) [2016.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0335) [p.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0335) [3---6.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0335)
26. [Jones](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [PW,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [Harding](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [G,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [Berry](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [P,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [Wiklund](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [I,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [Chen](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [WH,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [Kline](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [Leidy](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [N.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340)
[Development](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [first](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [validation](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [the](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [COPD](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [assessment](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [test.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340)
[Eur](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [Respir](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [J.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340) [2009;34:648---54.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0340)
27. [Kon](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [S,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [Canavan](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [JL,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [Jones](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [SE,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [Nolan](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [CM,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [Clark](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [AL,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [Dickson](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [MJ,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345)
[et](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [al.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [Minimum](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [clinically](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [important](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [difference](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [for](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [the](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [COPD](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345)
[Assesment](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [Test:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [a](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [prospective](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [analysis.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [Lancet](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [Respir](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345) [Med.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345)
[2014;2:195---203.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0345)
28. [Celli](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [BR,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [Cote](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [CG,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [Marin](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [JM,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [Casanova](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [C,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [Montes](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [de](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [Oca](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [M,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350)

[Mendez](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [RA,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [et](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [al.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [The](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [body-mass](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [index,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [airflow](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [obstruction,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350)

[dyspnea,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [exercise](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [capacity](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [index](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [chronic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [obstructive](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350)
[pulmonary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [disease.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [N](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [Engl](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [J](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [Med.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350) [2004;350:1005---12.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0350)
29. [Cote](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0355) [CG,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0355) [Celli](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0355) [BR.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0355) [Pulmonary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0355) [rehabilitation](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0355) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0355) [the](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0355) [BODE](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0355) [index](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0355)
[in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0355) [COPD.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0355) [Eur](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0355) [Respir](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0355) [J.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0355) [2005;26:630---6.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0355)
30. [Goldstein](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0360) [RS,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0360) [Gort](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0360) [EH,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0360) [Guyatt](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0360) [GH,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0360) [Feeny](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0360) [D.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0360) [Economic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0360) [analysis](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0360)
[of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0360) [respiratory](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0360) [rehabilitation.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0360) [Chest.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0360) [1997;112:370---9.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0360)
31. [Turnip](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [H,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [Ratnawati](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [A,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [Tulaar](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [A,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [Yunus](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [F,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [Kekalih](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [A.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [Compari-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365)
[son](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [the](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [effects](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [treadmill](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [ergocycle](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [exercise](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [on](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [the](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365)
[functional](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [capacity](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [quality](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [life](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [patients](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [with](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [chronic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365)
[obstructive](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [pulmonary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [disease.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [Med](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [J](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [Indonesia.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365) [2014;23:42---7.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0365)
32. [Vorrink](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [SNW,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [Kort](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [HSM,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [Troosters](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [T,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [Zanen](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [P,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [Lammers](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [JWJ.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [Effi-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370)
[cacy](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [an](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [mHealth](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [intervention](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [to](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [stimulate](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [physical](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [activity](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370)


[in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [COPD](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [patients](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [after](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [pulmonary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [rehabilitation.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [Eur](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [Respir](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370) [J.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370)
[2016;48:1019---29.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0370)
33. [Mendoza](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [L,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [Horta](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [P,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [Espinoza](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [J,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [Aguilera](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [M,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [Balmaceda](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [N,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [Castro](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375)
[A,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [et](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [al.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [Pedometers](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [to](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [enhance](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [physical](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [activity](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [COPD:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [a](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375)
[randomised](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [controlled](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [trial.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [Eur](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [Respir](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [J.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375) [2015;45:347---54.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0375)
34. [Jácome](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [C,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [Marques](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [A.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [Short-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [long-term](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [effects](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [pul-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380)
[monary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [rehabilitation](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [patients](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [with](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [mild](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [COPD:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [a](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [comparison](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380)
[with](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [patients](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [with](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [moderate](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [to](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [severe](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [COPD.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [Cardiopulm](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [Reha-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380)
[bil](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [Prev.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380) [2016;36:445---53.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0380)
35. [Gupta](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385) [N,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385) [Pinto](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385) [LM,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385) [Morogan](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385) [A,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385) [Bourbeau](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385) [J.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385) [The](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385) [COPD](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385) [assess-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385)
[ment](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385) [test:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385) [a](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385) [systematic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385) [review.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385) [Eur](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385) [Respir](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385) [J.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385) [2014;4:873---84.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0385)
36. [Bourne](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [S,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [DeVos](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [R,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [North](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [M,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [Chauhan](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [A,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [Green](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [B,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [Brown](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [T,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [et](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [al.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390)
[Online](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [versus](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [face-to-face](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [pulmonary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [rehabilitation](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [for](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [patients](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390)
[with](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [chronic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [obstructive](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [pulmonary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [disease:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [randomised](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [con-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390)
[trolled](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [trial.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [BMJ](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [Open.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390) [2017;7:e014580.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0390)
37. [Demeyer](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [H,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [Louvaris](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [Z,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [Frei](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [A,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [Rabinovich](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [RA,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [de](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [Jong](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [C,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395)
[Gimeno-Santos](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [E,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [et](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [al.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [Physical](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [activity](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [is](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [increased](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [by](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [a](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395)
[12-week](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [semiautomated](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [telecoaching](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [programme](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [patients](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395)
[with](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [COPD:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [a](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [multicentre](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [randomised](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [controlled](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [trial.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395) [Thorax.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395)
[2017;72:415---23.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0395)
38. [Holland](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [AE,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [Mahal](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [A,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [Hill](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [CJ,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [Lee](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [AL,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [Burge](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [AT,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [Cox](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [NS,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400)
[et](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [al.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [Home-based](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [rehabilitation](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [for](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [COPD](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [using](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [minimal](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400)
[resources:](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [a](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [randomized,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [controlled](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [equivalence](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [trial.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400) [Thorax.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400)
[2017;72:57---65.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0400)
39. [Atsou](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [K,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [Crequit](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [P,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [Chouaid](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [C,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [Hejblum](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [G.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [Simulation-based](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405)

[estimates](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [the](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [effectiveness](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [and](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [cost-effectiveness](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [pul-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405)
[monary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [rehabilitation](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [patients](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [with](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [chronic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [obstructive](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405)
[pulmonary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [disease](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [in](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [France.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [PLOS](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [ONE.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405) [2016;11:e0156514.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0405)
40. [Griffiths](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410) [TL,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410) [Phillips](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410) [CJ,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410) [Davies](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410) [S,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410) [Burr](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410) [ML,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410) [Campbell](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410) [IA.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410)
[Cost](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410) [effectiveness](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410) [an](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410) [outpatient](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410) [multidisciplinary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410) [pulmonary](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410)
[rehabilitation](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410) [programme.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410) [Thorax.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410) [2001;56:779---84.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0410)
41. [Clini](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [E,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [Foglio](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [K,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [Bianchi](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [L,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [Porta](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [R,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [Vitacca](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [M,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [Ambrosino](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [N.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [In-](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415)
[hospital](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [short-term](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [training](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [program](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [for](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [patients](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [with](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [chronic](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415)
[airway](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [obstruction.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [Chest.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415) [2001;120:1500---5.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0415)
42. [Goldstein](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0420) [RS,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0420) [Gort](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0420) [EH,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0420) [Stubbing](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0420) [D,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0420) [Avendano](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0420) [MA,](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0420) [Guyatt](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0420)
[GH.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0420) [Randomised](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0420) [controlled](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0420) [trial](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0420) [of](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0420) [respiratory](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0420) [rehabilitation.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0420)
[Lancet.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0420) [1994;344:1394---7.](http://refhub.elsevier.com/S2531-0437(18)30038-2/sbref0420)


-----

